Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC.

J Clin Oncol. 2018 Jul 19:JCO2017776112. doi: 10.1200/JCO.2017.77.6112. [Epub ahead of print]

PMID:
30024784
2.

Burden of Acute Myeloid Leukemia Among Older, Newly Diagnosed Patients: Retrospective Analysis of Data From the 2010-2012 Medicare Limited Data Set.

Sacks NC, Cyr PL, Louie AC, Liu Y, Chiarella MT, Sharma A, Chung KC.

Clin Ther. 2018 May;40(5):692-703.e2. doi: 10.1016/j.clinthera.2018.03.012. Epub 2018 Apr 17.

3.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH.

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14. No abstract available.

4.

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE.

Cancer. 2015 Jan 15;121(2):234-42. doi: 10.1002/cncr.28974. Epub 2014 Sep 15.

5.

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ.

Blood. 2014 May 22;123(21):3239-46. doi: 10.1182/blood-2013-12-540971. Epub 2014 Mar 31.

6.

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.

Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT, Mayer LD, Louie AC, Lancet JE.

Leuk Res. 2012 Oct;36(10):1283-9. doi: 10.1016/j.leukres.2012.07.006. Epub 2012 Jul 26.

PMID:
22840315
7.

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC.

J Clin Oncol. 2011 Mar 10;29(8):979-85. doi: 10.1200/JCO.2010.30.5961. Epub 2011 Jan 31.

8.

Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.

Batist G, Gelmon KA, Chi KN, Miller WH Jr, Chia SK, Mayer LD, Swenson CE, Janoff AS, Louie AC.

Clin Cancer Res. 2009 Jan 15;15(2):692-700. doi: 10.1158/1078-0432.CCR-08-0515.

9.

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy.

Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC.

J Clin Oncol. 1996 Aug;14(8):2410-1. No abstract available.

PMID:
8708739
10.

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC.

J Clin Oncol. 1995 Mar;13(3):688-96.

PMID:
7884429
11.
12.

Amsacrine (AMSA)--a clinical review.

Louie AC, Issell BF.

J Clin Oncol. 1985 Apr;3(4):562-92. Review. No abstract available.

PMID:
3884748
13.

Skin rash following therapy with mitomycin C.

Ritch PS, Louie AC.

Cancer. 1984 Jul 1;54(1):32-3.

PMID:
6232996
14.

Pulmonary toxicity of antitumor agents.

Muggia FM, Louie AC, Sikic BI.

Cancer Treat Rev. 1983 Dec;10(4):221-43. Review. No abstract available.

PMID:
6198083
15.

Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.

Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA, Merigan TC.

Blood. 1981 Oct;58(4):712-8.

16.

Immunotherapy of lung cancer. I. Review of clinical trials in non-small cell histologic types.

Mikulski SM, McGuire WP, Louie AC, Chirigos MA, Muggia FM.

Cancer Treat Rev. 1979 Sep;6(3):177-90. Review. No abstract available.

PMID:
394836
17.

Immunotherapy of lung cancer. II. Review of clinical trials in small cell carcinoma.

Mikulski SM, McGuire WP, Louie AC, Chirigos MA, Muggia FM.

Cancer Treat Rev. 1979 Jun;6(2):125-30. Review. No abstract available.

PMID:
226262
18.

"Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.

Von Hoff DD, Rozencweig M, Louie AC, Bender RA, Muggia FM.

Cancer Treat Rep. 1978 Feb;62(2):233-5. No abstract available.

PMID:
305823
19.

Five years of adjuvant treatment of osteosarcoma: more questions than answers.

Muggia FM, Louie AC.

Cancer Treat Rep. 1978 Feb;62(2):301-5. No abstract available.

PMID:
273478
20.

Visual abnormalities following nitrosourea treatment.

Louie AC, Turrisi AT, Muggia FM, Bono VH Jr.

Med Pediatr Oncol. 1978;5(1):245-7. No abstract available.

PMID:
745590
21.

High-dose methotrexate, not a conventional treatment.

Catane R, Bono VH Jr, Louie AC, Muggia FM.

Cancer Treat Rep. 1978 Jan;62(1):178-80. No abstract available.

PMID:
304763
22.

Current trends and prospects in surgical adjuvant trials.

Rozencweig M, von Hoff DD, Louie AC, Muggia FM.

Arch Geschwulstforsch. 1978;48(7):673-9.

PMID:
282827
23.

Effective adjuvant treatments. A brief review of U.S. clinical trials.

Louie AC, Rozencweig M, von Hoff DD, Muggia FM.

Arch Geschwulstforsch. 1978;48(7):653-8.

PMID:
282826

Supplemental Content

Loading ...
Support Center